I want to take this opportunity to write to Kurin customers, the Kurin Board, employees, and our Investors. Last week, Magnolia’s CEO, Greg Bullington, issued a press release announcing counter claims Magnolia filed in early August against Kurin, Inc., and making certain inaccurate and misleading representations regarding Kurin and its products.
While we are confident in our claims and defenses in the case against Magnolia and could argue them here, we want to allow the court to make its determinations based on the facts in due course. There are a couple of items, however, that I do want to address:
1) We firmly believe in diversion as a means to reduce contamination of blood cultures. The Kurin Lock™ IS the first FDA cleared diversion device on the market. The FDA has reviewed our data and given us clearance to market with 510(k) number k162233. To our knowledge, the FDA has never reviewed Steripath to determine whether or not it is a waived device, as Magnolia contends.
2) Our customers have seen that the Kurin Lock reduces skin contaminants, allowing them to significantly decrease their number of false positives. Our customers also understand that a product’s performance is only as good as their clinician’s adherence to protocols and achieving a high level of compliance. Automatic diversion requiring no user intervention increases the likelihood of compliance, which has a direct impact on outcomes. At Kurin, we work hard to partner with our customers to develop systems to drive and monitor compliance and to achieve meaningful results.
We look forward to the adjudication of the various claims by the court. For now, we only hope all companies will abide by the rule of law and make claims that are complete and true. At Kurin we strive to do the right thing, to be truthful and transparent. After all, if we cannot serve our customers well by bringing true value, then we do not deserve to remain in business.
Chairman and CEO
About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.